Study Evaluating Preference, Satisfaction and Ease of Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed Patients
NCT ID: NCT01385696
Last Updated: 2015-06-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
130 participants
INTERVENTIONAL
2011-06-30
2012-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Patients With COPD
NCT01915784
HandiHaler® vs. Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02172404
Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT02786927
Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler
NCT04147572
Assessment Of The Inhalation Profiles Of Four Dry Powder Inhalers In Patients With Variable Degrees Of Lung Obstruction
NCT01033669
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group A
Genuair first, HandiHaler second
Genuair® (Almirall S.A.)
Inhaler with only placebo, once daily, 14 days
HandiHaler® (Boehringer Ingelheim's)
Inhaler with only placebo, once daily, 14 days
group B
HandiHaler first, Genuair second
Genuair® (Almirall S.A.)
Inhaler with only placebo, once daily, 14 days
HandiHaler® (Boehringer Ingelheim's)
Inhaler with only placebo, once daily, 14 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Genuair® (Almirall S.A.)
Inhaler with only placebo, once daily, 14 days
HandiHaler® (Boehringer Ingelheim's)
Inhaler with only placebo, once daily, 14 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Naïve patients to the use of study inhalers
* Patients agreeing on participating and signing the Informed Consent Form
Exclusion Criteria
* Patients unable to read product package instructions and answer patient reported questionnaires
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Almirall, S.A.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jordi Estruch, Head of GMA
Role: STUDY_DIRECTOR
Almirall, S.A.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Almirall investigative site 3
Bonn, , Germany
Almirall investigative site 5
Koblenz, , Germany
Almirall investigative site 1
Enschede, , Netherlands
Almirall investigative site 2
Zutphen, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M/34273/32
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.